Is It Time To Buy Regeneron Pharmaceuticals Stock?

Regeneron (REGN) shares fell 19% after its COPD treatment, itepekimab, failed in a late-stage trial, impacting peak sales projections of $2-6 billion. This compounds existing pressures from weaker Eylea performance and FDA rejection of its pre-filled syringe. Despite the drop, the article suggests REGN may be undervalued, citing strong financials and profitability with price-to-sales (P/S) ratio of 4.6 vs. a figure of 3.0 for the S&P 500, and price-to-free cash flow (P/FCF) ratio of 16.4 compared to 20.5 for S&P 500, making it a potentially attractive buying opportunity despite risks from ongoing trials and market downturns.

Analysis

Regeneron Pharmaceuticals (REGN) experienced a significant 19% share price decline to $490 on May 30, now trading 60% below its 52-week high, following the failure of its partnered COPD treatment, itepekimab, in one of two late-stage clinical trials. This setback is substantial, as itepekimab was projected to achieve peak sales between $2 billion and $6 billion. The negative news compounds existing pressures from weaker-than-expected performance of its key drug Eylea and a recent FDA rejection for Eylea HD's pre-filled syringe due to third-party supplier issues. Despite these challenges and a 3.9% average revenue decline over the past three years (though revenues grew 7.5% in the last 12 months to $14 billion), the article posits that Regeneron may be undervalued. This assessment is supported by its price-to-free cash flow ratio of 16.4 and price-to-earnings ratio of 14.4, which are considerably lower than the S&P 500's 20.5 and 26.4, respectively, even as its price-to-sales ratio stands at 4.6 versus the S&P 500's 3.0. Regeneron maintains very strong profitability, evidenced by a 27.2% operating margin and a 31.9% net income margin, far exceeding market averages. Financially, the company is exceptionally stable, with a low 4.2% debt-to-equity ratio and a strong 22.2% cash-to-assets ratio. Future growth prospects are buoyed by Dupixent, which saw sales climb 19% to $3.7 billion last quarter with potential peak annual sales exceeding $20 billion, and a robust pipeline featuring over a dozen late-stage programs. The article concludes that Regeneron's overall financial health is 'Strong', suggesting the recent stock sell-off below $500 might be excessive.

Key Decisions for Investors

• Investors might consider the current depressed valuation of Regeneron as a potential buying opportunity for long-term gains, given its strong underlying profitability, financial stability, and significant growth drivers like Dupixent and its extensive late-stage pipeline.
• Carefully monitor upcoming results from ongoing clinical trials, especially concerning other COPD treatments, as further negative outcomes could exert additional downward pressure on the stock price.
• While Regeneron has demonstrated resilience in past market downturns, be mindful of its susceptibility to broader market volatility and macroeconomic uncertainties when considering an investment.